Other
Deferred taxes
Alnylam Pharmaceuticals Deferred taxes increased by 134.3% to $9.31M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.4%, from $9.64M to $9.31M. Over 3 years (FY 2022 to FY 2025), Deferred taxes shows a downward trend with a 15.3% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ1 2018
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Changes indicate shifts in the timing of tax liabilities, often driven by capital expenditures or changes in tax regulations.
Detailed definition
This metric reflects the tax effects of temporary differences between the carrying amounts of assets and liabilities for...
Peer comparison
Standard line item in the cash flow statement or tax reconciliation for all corporations.
Metric ID:
other_deferred_income_tax_expense_benefitHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$358.25K | -$358.25K | -$358.25K | -$358.25K | -$178.25K | -$178.25K | -$178.25K | -$178.25K | $454.00K | $340.00K | -$163.00K | -$107.39M | $9.64M | $9.74M | $5.60M | -$27.17M | $9.31M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +50.2% | +0.0% | +0.0% | +0.0% | +354.7% | -25.1% | -147.9% | <-999% | +109.0% | +1.0% | -42.5% | -585.4% | +134.3% |
| YoY Change | — | — | — | — | +50.2% | +50.2% | +50.2% | +50.2% | +354.7% | +290.7% | +8.6% | <-999% | >999% | >999% | >999% | +74.7% | -3.4% |
Range-$107.39M – $9.74M
CAGR+125.8%
Avg YoY Growth<-999%
Median YoY Growth+50.2%
Deferred taxes at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's deferred taxes?
- Alnylam Pharmaceuticals (ALNY) reported deferred taxes of $9.31M in Q1 2026.
- How has Alnylam Pharmaceuticals's deferred taxes changed year-over-year?
- Alnylam Pharmaceuticals's deferred taxes decreased by 3.4% year-over-year, from $9.64M to $9.31M.
- What is the long-term trend for Alnylam Pharmaceuticals's deferred taxes?
- Over 3 years (2022 to 2025), Alnylam Pharmaceuticals's deferred taxes has grown at a 15.3% compound annual growth rate (CAGR), from -$1.43M to -$2.20M.
- What does deferred taxes mean?
- The tax expense or benefit that will be paid or realized in future periods due to current accounting differences.